Term Sheet

The latest on private equity, M&A, deals and movements — from Wall Street to Silicon Valley

Venture capital deals

April 24, 2012: 9:51 AM ET

Argos Therapeutics Inc., a Durham, N.C.-based developer of immunotherapies for the treatment of cancer and infectious diseases, has raised $25 million in Series D funding. Forbion Capital led the round, and was joined by fellow return backers like TVM Capital, Lumira Capital, Intersouth Partners, Caisse de dépôt et placement du Québec, Morningside Group and Aurora Funds. The company recently withdrew its IPO registration due to "market conditions," and previously raised over $100 million in VC funding. www.argostherapeutics.com

MiRagen Therapeutics Inc., a Boulder, Colo.-based developer of microRNA-based therapeutics for the treatment of cardiovascular and muscle disease, has raised $20 million in Series B funding. Remeditex Ventures led the round, and was joined by return backers Atlas Venture, Boulder Ventures, Amgen Ventures and Broadview Ventures. www.miragenrx.com

Terascala Inc., an Avon, Mass.-based company that accelerates big data applications through storage I/O optimization, has raised $14 million in Series B funding. Undisclosed strategic backers were joined by existing investor Ascent Venture Partners. www.terascala.com

Singly, a San Francisco-based developer of a software platform and service for personal data, has raised around $6.5 million in VC funding led by Foundry Group. www.singly.com

Citrus Lane, a Mountain View, Calif.-based subscription delivery service for infant and toddler products, has raised $5.1 million in Series A funding from GGV Capital and seed backer Greylock Partners. www.citruslane.com

Locu, a Cambridge, Mass.-based data structuring startup, has raised $4 million in Series A funding. General Catalyst Partners led the round, and were joined by Lowercase Capital, Lightbank, SV Angel and return backers Quotidian Ventures, Matt Ocko, Naval Ravikant and Babak Nivi. www.locu.com

Oligomerix Inc., a New York–based developer of disease-modifying therapeutics for Alzheimer's disease and related neurodegenerative disorders, has raised around $2 million in Series A funding (including debt conversion). Backers include Wheatley MedTech Partners, Wheatley New York Partners and Durand Venture Associates. www.oligomerix.com

Zauber, an Argentina-based software boutique and lab, has raised $1 million in first-round funding from AxVentures-Pymar Fund. www.zauberlabs.com

LED Engin Inc., a San Jose, Calif.-based solid-state lighting company, has raised an undisclosed amount of Series E funding. GVT Fund led the round, and was joined by MSIVC and return backers WK Technology Fund, Partech International and NGP Energy Technology Partners. www.ledengin.com

Want deal news in your inbox each morning? Get Term Sheet!

Posted in:
Join the Conversation
About This Author
Dan Primack
Dan Primack
Senior Editor, Fortune

Dan Primack joined Fortune.com in September 2010 to cover deals and dealmakers, from Wall Street to Sand Hill Road. Previously, Dan was an editor-at-large with Thomson Reuters, where he launched both peHUB.com and the peHUB Wire email service. In a past journalistic life, Dan ran a community paper in Roxbury, Massachusetts. He currently lives just outside of Boston.

Email a Tip | @danprimack | RSS
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Powered by WordPress.com VIP.